KR100615345B1 - 의약으로서 사용되는 포스핀산 및 포스폰산 유도체, 및 이를 포함하는 약제학적 조성물 - Google Patents

의약으로서 사용되는 포스핀산 및 포스폰산 유도체, 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100615345B1
KR100615345B1 KR1020017000698A KR20017000698A KR100615345B1 KR 100615345 B1 KR100615345 B1 KR 100615345B1 KR 1020017000698 A KR1020017000698 A KR 1020017000698A KR 20017000698 A KR20017000698 A KR 20017000698A KR 100615345 B1 KR100615345 B1 KR 100615345B1
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
integer
formula
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017000698A
Other languages
English (en)
Korean (ko)
Other versions
KR20010071940A (ko
Inventor
슈독만프레트
슈밥빌프리트
촐러게르하르트
바르트닉엑카르트
뷔트너프랑크
바이트만클라우스-울리히
Original Assignee
사노피-아벤티스 도이칠란트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19831980A external-priority patent/DE19831980A1/de
Priority claimed from DE19921680A external-priority patent/DE19921680A1/de
Application filed by 사노피-아벤티스 도이칠란트 게엠베하 filed Critical 사노피-아벤티스 도이칠란트 게엠베하
Publication of KR20010071940A publication Critical patent/KR20010071940A/ko
Application granted granted Critical
Publication of KR100615345B1 publication Critical patent/KR100615345B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017000698A 1998-07-16 1999-07-07 의약으로서 사용되는 포스핀산 및 포스폰산 유도체, 및 이를 포함하는 약제학적 조성물 Expired - Fee Related KR100615345B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19831980.0 1998-07-16
DE19831980A DE19831980A1 (de) 1998-07-16 1998-07-16 Sulfonylaminophosphin- und phosphonsäurederivate
DE19921680A DE19921680A1 (de) 1999-05-12 1999-05-12 Sulfonylaminophosphin- und phosphonsäurederivate
DE19921680.0 1999-05-12

Publications (2)

Publication Number Publication Date
KR20010071940A KR20010071940A (ko) 2001-07-31
KR100615345B1 true KR100615345B1 (ko) 2006-08-25

Family

ID=26047473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017000698A Expired - Fee Related KR100615345B1 (ko) 1998-07-16 1999-07-07 의약으로서 사용되는 포스핀산 및 포스폰산 유도체, 및 이를 포함하는 약제학적 조성물

Country Status (21)

Country Link
US (2) US6235727B1 (cg-RX-API-DMAC7.html)
EP (1) EP1097159B1 (cg-RX-API-DMAC7.html)
JP (1) JP4567886B2 (cg-RX-API-DMAC7.html)
KR (1) KR100615345B1 (cg-RX-API-DMAC7.html)
CN (1) CN1194978C (cg-RX-API-DMAC7.html)
AR (1) AR019390A1 (cg-RX-API-DMAC7.html)
AT (1) ATE227295T1 (cg-RX-API-DMAC7.html)
AU (1) AU754050B2 (cg-RX-API-DMAC7.html)
BR (1) BR9912085A (cg-RX-API-DMAC7.html)
CA (1) CA2337828C (cg-RX-API-DMAC7.html)
CZ (1) CZ300780B6 (cg-RX-API-DMAC7.html)
DE (1) DE59903329D1 (cg-RX-API-DMAC7.html)
DK (1) DK1097159T3 (cg-RX-API-DMAC7.html)
ES (1) ES2187171T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0102837A3 (cg-RX-API-DMAC7.html)
ID (1) ID27133A (cg-RX-API-DMAC7.html)
PL (1) PL199234B1 (cg-RX-API-DMAC7.html)
PT (1) PT1097159E (cg-RX-API-DMAC7.html)
RU (1) RU2224762C2 (cg-RX-API-DMAC7.html)
TR (1) TR200100084T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000004030A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002411A1 (en) * 1999-07-06 2001-01-11 Methylgene Inc. SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE
MXPA05001544A (es) * 2002-08-08 2005-04-19 Smithkline Beecham Corp Compuestos de tiofeno.
JP4450192B2 (ja) 2004-07-01 2010-04-14 信越化学工業株式会社 珪素複合体及びその製造方法並びに非水電解質二次電池用負極材
AU2007268081A1 (en) * 2006-05-22 2007-12-06 Methylgene Inc. Novel sulfonamidomethylphosphonate inhibitors of beta-lactamase
AU2007332968B2 (en) * 2006-05-22 2013-07-11 Methylgene Inc. Novel inhibitors of beta-lactamase
JP5399219B2 (ja) * 2009-11-24 2014-01-29 株式会社ケイティーバイオ 関節リウマチに対するヒト型抗TNFα抗体薬の薬効予測方法、及び薬効予測装置
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996040A (en) * 1974-06-28 1976-12-07 Monsanto Company Increasing sucrose content of sugar cane employing N-phenylsulfonamido-N-phosphonomethyl glycine and certain derivatives thereof
JPS6137800A (ja) * 1984-07-31 1986-02-22 Kyowa Hakko Kogyo Co Ltd 含リンペプチド
DE3435156A1 (de) * 1984-09-25 1986-04-03 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung der stereoisomeren von 1-amino-alkylphosphonsaeuren oder 1-aminoalkylphosphinsaeuren
JPS62148493A (ja) * 1985-12-24 1987-07-02 Teijin Ltd 新規ホスホン酸誘導体および除草剤
EP0243173B1 (en) * 1986-04-24 1991-06-26 Fujisawa Pharmaceutical Co., Ltd. New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
JP2764262B2 (ja) 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (cg-RX-API-DMAC7.html) 1990-07-05 1993-03-01 Hoffmann La Roche
JP2525977B2 (ja) * 1991-10-17 1996-08-21 昭和電工株式会社 N−アシルアミノメチルホスホン酸の製造法
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU690703B2 (en) 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
EP0958283A1 (de) * 1997-01-27 1999-11-24 Nycomed Austria GmbH Neue verbindungen mit hämoregulatorischer wirkung
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
ATE210639T1 (de) * 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren

Also Published As

Publication number Publication date
HK1038363A1 (en) 2002-03-15
CA2337828C (en) 2010-08-17
CA2337828A1 (en) 2000-01-27
ES2187171T3 (es) 2003-05-16
HUP0102837A2 (hu) 2001-12-28
WO2000004030A1 (de) 2000-01-27
EP1097159B1 (de) 2002-11-06
AR019390A1 (es) 2002-02-20
CZ300780B6 (cs) 2009-08-12
CN1309660A (zh) 2001-08-22
AU754050B2 (en) 2002-10-31
CZ2001144A3 (en) 2001-05-16
US6500811B2 (en) 2002-12-31
BR9912085A (pt) 2001-04-10
AU4908299A (en) 2000-02-07
PL199234B1 (pl) 2008-08-29
TR200100084T2 (tr) 2001-07-23
HUP0102837A3 (en) 2002-04-29
ATE227295T1 (de) 2002-11-15
US20020082246A1 (en) 2002-06-27
DK1097159T3 (da) 2003-03-10
JP2002520418A (ja) 2002-07-09
US6235727B1 (en) 2001-05-22
DE59903329D1 (en) 2002-12-12
RU2224762C2 (ru) 2004-02-27
KR20010071940A (ko) 2001-07-31
ID27133A (id) 2001-03-01
JP4567886B2 (ja) 2010-10-20
PL345653A1 (en) 2002-01-02
EP1097159A1 (de) 2001-05-09
PT1097159E (pt) 2003-03-31
CN1194978C (zh) 2005-03-30

Similar Documents

Publication Publication Date Title
JP4177483B2 (ja) スルホニルアミノカルボン酸
JP4177484B2 (ja) 置換されたジアミノカルボン酸
SK64993A3 (en) Hydroxamic acid derivatives, method of their preparation and medicaments with their content
WO1997012903A1 (en) Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
KR100655632B1 (ko) N-아릴설포닐 아미노산 오메가 아미드
RU2224762C2 (ru) Производные фосфиновых и фосфоновых кислот, способ их получения и фармацевтическая композиция на их основе
KR19980086989A (ko) 치환된 6- 및 7- 아미노-테트라하이드로이소퀴놀린 카복실산
MXPA01000400A (en) Phosphinous and phosphonic acid derivatives used as medicaments
RU2196768C2 (ru) Замещенные диаминокарбоновые кислоты
HUP9902700A2 (hu) Hidroxámsavszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
MXPA98003661A (en) Acids sulfonilaminocarboxili
DE19921680A1 (de) Sulfonylaminophosphin- und phosphonsäurederivate
HK1038363B (en) Phosphinous and phosphonic acid derivatives used as medicaments
MXPA98003660A (en) Acidos diaminocarboxilicos sustitui

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100811

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110818

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110818

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000